Literature DB >> 29504793

How does exposure therapy work? A comparison between generic and gastrointestinal anxiety-specific mediators in a dismantling study of exposure therapy for irritable bowel syndrome.

Hugo Hesser1, Erik Hedman-Lagerlöf2, Erik Andersson3, Perjohan Lindfors4, Brjánn Ljótsson3.   

Abstract

OBJECTIVE: Systematic exposure is potentially an effective treatment procedure for treating irritable bowel syndrome (IBS), but little is known about the processes by which it achieves its effect on outcome. The aim of this study was to identify mediators in a previously published randomized dismantling trial in which participants with IBS were randomized to Internet-delivered cognitive-behavioral treatment (ICBT) that incorporated systematic exposure or to the same treatment protocol without exposure (ICBT-WE).
METHOD: Weekly measurements of gastrointestinal anxiety-specific process variables (behavioral avoidance, gastrointestinal-specific anxiety) based on the gastrointestinal symptom-specific anxiety model, generic process variables (self-efficacy and mindful nonreactivity), and treatment outcome (IBS symptoms) were obtained from 309 participants with IBS. Growth models and cross-lagged panel models, estimated within structural equation modeling, were employed to evaluate mediators of outcome.
RESULTS: Parallel process growth modeling showed that behavioral avoidance, gastrointestinal-specific anxiety, self-efficacy mediated the incremental effect of ICBT compared to ICBT-WE. The mediated effect of avoidance was stronger for individuals scoring high on the avoidance variable at 1st measurement point. Cross-lagged regression analyses with random effects revealed that behavioral avoidance and gastrointestinal-specific anxiety had a stronger effect on subsequent symptom change rather than vice versa, whereas mindful nonreactivity and self-efficacy displayed the opposite pattern.
CONCLUSIONS: The evidence collectively provided support for the hypothesis that exposure for IBS achieves its positive results by virtue of changing gastrointestinal anxiety-specific processes rather than generic processes. IBS-specific behavioral avoidance emerged as the most clear-cut mediator of the specific effect of exposure on outcome. (PsycINFO Database Record (c) 2018 APA, all rights reserved).

Entities:  

Mesh:

Year:  2018        PMID: 29504793     DOI: 10.1037/ccp0000273

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  10 in total

1.  Discriminant and convergent validity of the GSRS-IBS symptom severity measure for irritable bowel syndrome: A population study.

Authors:  Brjánn Ljótsson; Michael Jones; Nicholas J Talley; Lars Kjellström; Lars Agréus; Anna Andreasson
Journal:  United European Gastroenterol J       Date:  2020-01-14       Impact factor: 4.623

2.  A preliminary naturalistic clinical case series study of the feasibility and impact of interoceptive exposure for eating disorders.

Authors:  James F Boswell; Lisa M Anderson; Jennifer M Oswald; Erin E Reilly; Sasha Gorrell; Drew A Anderson
Journal:  Behav Res Ther       Date:  2019-02-15

3.  Brain-gut psychotherapies: Promising tools to address gastrointestinal problems in patients with eating disorders.

Authors:  Jennifer E Wildes; Alyse Bedell; Andrea K Graham; Meredith Kells
Journal:  Int J Eat Disord       Date:  2021-05-19       Impact factor: 4.861

4.  Preliminary investigation of the associations between psychological flexibility, symptoms and daily functioning in people with chronic abdominal pain.

Authors:  Lin Yu; Yoram Inspector; Lance M McCracken
Journal:  Br J Pain       Date:  2020-06-03

5.  Cost-effectiveness of internet-delivered cognitive-behavioural therapy for adolescents with irritable bowel syndrome.

Authors:  Filipa Sampaio; Marianne Bonnert; Ola Olén; Erik Hedman; Maria Lalouni; Fabian Lenhard; Brjánn Ljótsson; Richard Ssegonja; Eva Serlachius; Inna Feldman
Journal:  BMJ Open       Date:  2019-01-24       Impact factor: 2.692

6.  A unified Internet-delivered exposure treatment for undifferentiated somatic symptom disorder: single-group prospective feasibility trial.

Authors:  Jonna Hybelius; Anton Gustavsson; Sandra Af Winklerfelt Hammarberg; Eva Toth-Pal; Robert Johansson; Brjánn Ljótsson; Erland Axelsson
Journal:  Pilot Feasibility Stud       Date:  2022-07-19

7.  Parental responses and catastrophizing in online cognitive behavioral therapy for pediatric functional abdominal pain: A mediation analysis of a randomized controlled trial.

Authors:  Maria Lalouni; Aleksandra Bujacz; Marianne Bonnert; Karin B Jensen; Anna Rosengren; Erik Hedman-Lagerlöf; Eva Serlachius; Ola Olén; Brjánn Ljótsson
Journal:  Front Pain Res (Lausanne)       Date:  2022-10-03

8.  Validation of child-adapted short scales for measuring gastrointestinal-specific avoidance and anxiety.

Authors:  Maria Lalouni; Ola Olén; Johan Bjureberg; Marianne Bonnert; Trudie Chalder; Erik Hedman-Lagerlöf; Silje Endresen Reme; Eva Serlachius; Brjánn Ljótsson
Journal:  Acta Paediatr       Date:  2022-05-27       Impact factor: 4.056

9.  Return on investment of internet delivered exposure therapy for irritable bowel syndrome: a randomized controlled trial.

Authors:  Hugo Wallén; Perjohan Lindfors; Erik Andersson; Erik Hedman-Lagerlöf; Hugo Hesser; Nils Lindefors; Cecilia Svanborg; Brjánn Ljótsson
Journal:  BMC Gastroenterol       Date:  2021-07-13       Impact factor: 3.067

10.  Specific and common mediators of gastrointestinal symptom improvement in patients undergoing education/support vs. cognitive behavioral therapy for irritable bowel syndrome.

Authors:  Jeffrey M Lackner; James Jaccard
Journal:  J Consult Clin Psychol       Date:  2021-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.